PPB employs technology from US to detect substandard and falsified medical products
The Pharmacy and Poisons Board (PPB) has announced that it will use new US technology to detect substandard and falsified medical products.
In a statement on Wednesday, December 11, 2024, PPB said it is partnering with Missions for Essential Drugs and Supplies (MEDS) to implement advanced Near Infrared Technology (NIR) known as Pillscan.
“The Pharmacy and Poisons Board (PPB), in collaboration with Missions for Essential Drugs and Supplies (MEDS), has commenced the implementation of advanced Near Infrared Technology (NIR) known as Pillscan. Acquired from Global Health Labs USA with support from the Global Fund, this cutting-edge technology is set to enhance PPB’s quality control systems by detecting substandard and falsified medical products, thereby ensuring the safety, quality, and effectiveness of medicines,” PPB stated.
The implementation phase began on Monday, December 9, 2024, at the PPB headquarters. It includes personnel re-training conducted by software engineers from Global Health Labs USA, equipment qualification, and the development of a comprehensive library to support the technology’s operation.
The board will use the Pillscan for screening medical production at key entry points and at its regional offices.
The new technology will be used alongside the existing control measures employed by the board.
Author
Francis Muli
Francis Muli is a passionate digital journalist with over seven years of experience in crafting compelling stories across various platforms. His major focus is in business, politics and current affairs. He brings a keen eye for detail and a commitment to uncovering the truth. He has contributed to leading publications across the country. When not chasing stories, you can find Muli exploring new technologies, attending local events, or reading fiction. Connect with Francis Muli on X @FMuliKE and Facebook (Francis Muli) to follow his latest stories and insights.
View all posts by Francis Muli
